MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Name: MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
Published: 2018
License: Public Domain

Merus B.V. · 2018

ClinicalTrials.gov · Datasets · License: Public Domain · 2018

Open Source ↗

antibodies cytokines

breast cancer metastatic, bispecific antibody immunoglobulin gamma-1(igg1), human epidermal growth factor receptor (her)2, her3, mcla-128, antibodies, bispecific, immunologic factors, cytokines, combination trastuzumab with and without vinorelbine, zenocutuzumab, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Related documents